Podcast
A Nursing Perspective on PARP Inhibitors in Prostate Cancer
Release Date: June 30, 2022
Expiration Date: June 29, 2023
Not certified for credit.
Begin »
Program Overview
Program Description
The treatment landscape of metastatic castrate-resistant prostate cancer (mCRPC) is continually evolving. In this podcast, an advanced practice provider discusses recent evidence on PARP inhibitors for mCRPC and how they incorporate these data into clinical practice.
Topics include the role of PARP inhibitors for mCRPC with mutations in homologous recombination repair genes, testing for BRCA1/2 and other homologous recombination repair mutations, approved indications for olaparib and rucaparib, managing adverse events with approved PARP inhibitors, and a look at the future of PARP inhibition in mCRPC.
Format
Podcast
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Brenda Martone, MSN, ANP-BC, AOCNP
- Nurse Practitioner
- Genitourinary Oncology
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Chicago, Illinois
Details
This activity is supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme Corp.
Brenda Martone, MSN, ANP-BC, AOCNP, has no relevant financial relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 104922O-pod2